AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Q. I have two sons, 5 and 7. I do not allow my children more than a half hour a day on their iPad. My partner uses screen time as ...
Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback